Verenium (NASDAQ: [[ticker:VRNM]]), a Cambridge, MA-based biofuel firm, filed a shelf registration statement covering the potential issuance of up to $150 million of stock, debt securities, or warrants. The filing also covers the potential resale of 3 million shares of Verenium common stock by Syngenta (with which Verenium has a strategic alliance) and its affiliates. Verenium was formed just five months ago through the merger of Cambridge’s Celunol and San Diego’s Diversa.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
